Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ReNeuron Group Plc logo — Developing the next generation of Engineered Exosomes.

ReNeuron Group Plc

Developing the next generation of Engineered Exosomes.

Founded 1997 United Kingdom Bridgend, United Kingdom 27 employees Post-IPO Equity Total: $110.95M Biotechnology, Health Care +1

General Information

Company Name ReNeuron Group Plc
Founded Year 1997
Location United Kingdom Bridgend, United Kingdom
Founders / Decision Makers
Team member
Employees 27
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with ReNeuron Group Plc. To contact ReNeuron Group Plc, visit reneuron.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ReNeuron Group Plc compare?

A PDF of ReNeuron Group Plc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ReNeuron Group Plc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ReNeuron Group Plc

ReNeuron Group Plc is a biotechnology startup based in United Kingdom that is dedicated to developing the next generation of Engineered Exosomes. The company's flagship technology, CustomEx exosome platform, is designed to produce exosomes with unique tissue targeting tropisms, allowing for the delivery of a payload of choice to a preferred cell type. ReNeuron's ultimate mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs in the fields of Biotechnology and Health Care. Founded in 1997, ReNeuron Group Plc has garnered significant attention from investors. Its last investment of £68.40MPost-IPO Equity was secured on 10 July 2015 from a notable investor, Woodford Patient Capital Trust. This infusion of capital underscores the growing interest in ReNeuron's innovative approach to addressing unmet medical needs through exosome therapeutics. With a clear focus on leveraging its proprietary technology to advance the field of regenerative medicine, ReNeuron holds promise as a key player in the biotech landscape.

Business keywords: Exosome technology, CustomEx platform, Tissue targeting, Payload delivery, Cell-specific targeting, Therapeutic development, Disease treatment, Partnership, Drug delivery, Regenerative medicine

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £68.40M 1
Woodford Patient Capital Trust
Woodford Patient Capital Trust
10 Jul 2015
Post IPO Equity £25.35M 1
Arthurian Life Sciences
Arthurian Life Sciences
22 Jul 2013
Post IPO Equity €4.70M -
22 Feb 2010
Post IPO Equity €5.00M 1
Matrix Corporate Capital
26 Nov 2009
Venture Round $7.50M 1
Excalibur Fund Managers
Excalibur Fund Managers
01 Jan 1997

ReNeuron Group Plc Alternatives & Competitors

View All Alternatives
ReNeuron Group Plc vs
Bright Peak Therapeutics
Bright Peak Therapeutics Switzerland

Better Biologics Through Chemistry

Series C
56 employees
Biotechnology, Health and Wellness
Compare ReNeuron Group Plc vs Bright Peak Therapeutics
ReNeuron Group Plc vs
Entelexo Biotherapeutics
Entelexo Biotherapeutics United States

Entelexo has created a novel platform technology for engineering exosomes as a new approach to treat...

2 employees
Biotechnology, Health Care
Compare ReNeuron Group Plc vs Entelexo Biotherapeutics
ReNeuron Group Plc vs
Evox Therapeutics Ltd
Evox Therapeutics Ltd United Kingdom

Changing the course of CNS disease

Series C
36 employees
Biotechnology, Health Care
Compare ReNeuron Group Plc vs Evox Therapeutics Ltd
View all alternatives

FAQ About ReNeuron Group Plc

Developing the next generation of Engineered Exosomes.
ReNeuron Group Plc was founded in 1997.
ReNeuron Group Plc is headquartered in Bridgend, United Kingdom.
ReNeuron Group Plc operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Exosome technology, CustomEx platform, Tissue targeting and Payload delivery.
ReNeuron Group Plc has approximately 27 employees.
ReNeuron Group Plc has completed 5 funding rounds, raising a total of $110.95M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to ReNeuron Group Plc include Bright Peak Therapeutics, Entelexo Biotherapeutics, Evox Therapeutics Ltd, Endogena Therapeutics, Inc., HAYA Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ReNeuron Group Plc and Bright Peak Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ReNeuron Group Plc, https://bouncewatch.com/company/reneuron-group-plc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout